BC
CGEM icon

Boxer Capital’s Cullinan Oncology CGEM Stock Holding History

Boxer Capital’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-907,895
Closed -$15.2M – 10
2024
Q3 		$15.2M Buy
907,895
+250,000
+38% +$4.43M 0.75% 37
2024
Q2 		$11.5M Buy
+657,895
New +$14M 0.6% 41
2023
Q4 		– Sell
-1,074,082
Closed -$9.72M – 56
2023
Q3 		$9.72M Hold
1,074,082
– – 0.52% 41
2023
Q2 		$11.6M Hold
1,074,082
– – 0.54% 46
2023
Q1 		$11M Hold
1,074,082
– – 0.54% 42
2022
Q4 		$11.3M Hold
1,074,082
– – 0.6% 42
2022
Q3 		$13.8M Hold
1,074,082
– – 0.77% 40
2022
Q2 		$13.8M Hold
1,074,082
– – 0.87% 39
2022
Q1 		$11.2M Hold
1,074,082
– – 0.58% 42
2021
Q4 		$16.6M Hold
1,074,082
– – 0.64% 36
2021
Q3 		$24.2M Hold
1,074,082
– – 0.85% 34
2021
Q2 		$27.7M Hold
1,074,082
– – 0.98% 28
2021
Q1 		$44.8M Buy
+1,074,082
New +$43.6M 1.52% 18

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Boxer Capital's CGEM Position: Q4 2024 in Review

Boxer Capital sold out of Cullinan Oncology (CGEM) in Q4 2024, closing a stake of 907,895 shares — an estimated $15.2M sold.

Boxer Capital first reported a position in CGEM in Q1 2021 and held it in 13 quarters. The position peaked at $44.8M in Q1 2021. 146 funds tracked by Wall St. Rank hold CGEM as of Q4 2024.

  • Boxer Capital reported no remaining Cullinan Oncology position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 907,895 Cullinan Oncology shares in Q4 2024, an estimated $15.2M.
  • Boxer Capital first reported a position in Cullinan Oncology in Q1 2021 and held it in 13 quarters.
  • Boxer Capital's Cullinan Oncology position peaked at $44.8M in Q1 2021.
  • 146 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.